Skip to main content
PLIANT THERAPEUTICS, INC. logo

PLIANT THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · PLRX ISIN · US7291391057 LEI · 5493002Q5LITR7VHZH02 US Professional, scientific and technical activities
Open in API
Filings indexed 403 across all filing types
Latest filing 2023-03-08 Director's Dealing
Country US United States of America
Listing US PLRX

About PLIANT THERAPEUTICS, INC.

https://pliantrx.com/

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of fibrosis and related diseases. The company leverages its expertise in integrin biology to create tissue-specific treatments. Its therapeutic approach centers on modulating integrin activity and inhibiting TGF-β1 signaling, which are key molecular drivers of fibrosis. Pliant utilizes its proprietary discovery platform to advance a pipeline of integrin-based product candidates, aiming to provide safer and more effective therapies for patients.

Recent filings

Filing Released Lang Actions
FORM 3 SUBMISSION
Director's Dealing
2023-03-08 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 6, 2023, by Pliant Therapeutics, Inc. The content focuses on the departure and appointment of directors, changes in the board size, committee assignments, and director compensation arrangements. There is no financial data, earnings information, or report publication mentioned. The primary subject is changes in the company's board of directors and senior management. According to the filing definitions, this fits the category 'Board/Management Information (MANG)'. The document length is 5428 characters, which is sufficient to contain substantive information rather than a brief announcement. Therefore, the classification is MANG with high confidence.
2023-03-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the termination of a material definitive agreement between the company and Novartis, detailing the cessation of a collaboration and license agreement. There are no financial statements or detailed financial performance data included, only a description of the event and its implications. This fits the definition of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories. The document length is about 5,098 characters, which is sufficient for a substantive announcement but does not constitute a full financial report or earnings release. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-02-23 English
SC 13G/A
Major Shareholding Notification
2023-02-14 English
SC 13G/A
Major Shareholding Notification
2023-02-14 English
CHI ADVISORS LLC
Major Shareholding Notification
2023-02-13 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.